Bayer Aktiengesellschaft

Reilinde Wittka

Hans-Georg Heine

Klaus Urbahns

Thomas Glaser

Jean-Marie-Viktor De Vry

Bodo Junge

Henning Sommermeyer

Rudolf Schohe-Loop

Siegfried Goldmann

Hartmund Wollweber

Egbert Wehinger

Frank Mauler

Otto Behner

Jean-Marie Viktor De Vry

The invention relates to the use of 5-substituted pyridine- and hexahydroquinoline-3-carboxylic acid derivatives, some of which are known, for the production of medicaments, in particular for the treatment of cerebral disorders.

Use of 5-substituted pyridine and hexahydroquinoline-3 carboxylic acid derivatives for treating diseases of the central nervous system

The present invention relates to the new use of 1,2-bridged 1,4-dihydropyridines which are known in some cases, of the general formula (I) ##STR1## in which R.sup.1 to R.sup.4 and a have the meaning indicated in the description, processes for their preparation and their use as medicaments, as selective potassium channel modulators, in particular for the treatment of the central nervous system.

Use of 1,2-Bridged 1,4-dihydropyridines as medicaments

The present invention relates to new 2,3-bridged 1,4-dihydropyridines of the general formula (I), ##STR1## in which R, R.sup.1, R.sup.2, D and E have the meaning given in the description, processes for their preparation and their use as medicaments, preferably for treatment of the central nervous system.

2,3-bridged 1,4-dihydropyridines, and their use as medicaments

Use of 1,2-bridged 1,4-dihydropyridines as medicaments

The present invention relates to the use of 1,4-dihydropyridine-3,5-dicarboxylic acid esters, some of which are known, of the general formula (I) ##STR1## in which A and R.sup.1 -R.sup.3 have the meaning given in the description, as medicaments, in particular for treatment of the central nervous system, and new selected active compounds.

Use of 1,4-dihydropyridine-3,5-dicarboxylic acid esters as medicaments

The present invention relates to the new use of 1-alkyl-3,5-diacyl-1,4-dihydropyridines which are known in some cases, of the general formula (I) ##STR1## in which R.sup.1 to R.sup.4 have the meaning indicated in the description, processes for their preparation and their use as medicaments, as selective potassium channel modulators, in particular for the treatment of the central nervous system.

5-acyl-1,4-dihydropyridines

Use of substituted 6-amino-4H-pyrans

Use of N-substituted phenothiazines

The substituted 4H-pyrans are prepared by reacting either aldehydes or ylidene compounds with suitably substituted .beta.-diketones. The substituted 4H-pyrans according to the invention are suitable as active compounds in medicaments, in particular for the treatment of disorders of the central nervous system.

Substituted 4H-pyrans

Dioxo-thiopyrano-pyridine-carboxylic acid derivatives and their use as

The invention relates to the use of acyl-substituted aminopyrans for the production of medicaments, in particular of medicaments for the treatment of disorders of the central nervous system.

Use of acyl-substituted aminopyrans

The application relates to substituted 4-phenyl-6-amino-nicotinic acid derivatives for therapeutic use, to novel active compounds and to their use as cerebrally active agents. The active compounds are prepared by oxidizing appropriately substituted dihydropyridines according to customary methods.

Substituted 4-phenyl-6-amino-nicotinic acid compounds useful in the

1,4-dihydropyridine-3,5-dicarboxylic acid esters in treatment of

The present invention relates to the new use of 6-amino-5-nitro- and -5-cyano-1,4-dihydropyridines of the general formula (I) ##STR1## in which A, D and R.sup.1 -R.sup.4 have the meaning given in the description, new 6-acylamino-dihydropyridines, processes for their preparation and their use as medicaments as selective potassium channel modulators, in particular for treatment of the central nervous system.

6-amino-1,4-dihydropyridine compounds as medicaments for treatment of

The cyclohexadiene derivatives are prepared by reaction of cyclohexanones with amines and subsequent dehydration. The compounds are effective in the treatment of depression on account of their property of being selective modulators of calcium channel-dependent potassium channels.

Growing community of inventors

Koln, Germany

Reilinde Wittka